Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific hT2R9 alleles and their disparate activity in functional assays with the same biter ligands. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands and related compounds. These compounds may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste. Also T2R ligands may be used as therapeutics to treat and modulate T2R associated gastrointestinal and metabolic functions as well as treat gastrointestinal and metabolic diseases such as eating disorders, food sensing, food absorption, obesity, diabetes, Crohn's disease, celiac disease, et al.
1. An assay for identifying a compound which modulates a human T2R bitter taste receptor polypeptide wherein said polypeptide specifically responds to caffeine, which assay comprises: i. screening a compound for its effect on caffeine to induce the activation of (1) said bitter taste receptor polypeptide which is a polypeptide that possesses at least 90% sequence identity to the polypeptide of SEQ ID NO:36 (2) or is a polypeptide encoded by a nucleic acid sequence contained in SEQ ID NO: 37, and/or (3) is a polypeptide encoded by a nucleic acid sequence that hybridizes to the complement of the nucleic acid sequence of SEQ ID:35 under stringent hybridization conditions, which possesses at least 90% sequence identity to the polypeptide of SEQ ID NO:36 and ii. determining whether said compound modulates bitter taste based on its effect on the activation of said polypeptide by caffeine; and iii. identifying said compound as a potential bitter taste modulator if it modulates the activation of said polypeptide by caffeine.
2. The assay of claim 1 , wherein polypeptide possesses at least 90% sequence identity to the polypeptide of SEQ ID NO:36.
3. The assay of claim 1 , wherein the polypeptide possesses at least 95% sequence identity to the polypeptide of SEQ ID NO:36.
4. The assay of claim 1 , wherein the polypeptide possesses at least 98% sequence identity to the polypeptide of SEQ ID NO:36.
5. The assay of claim 1 , wherein the polypeptide possesses at least 99% sequence identity to the polypeptide of SEQ ID NO:36.
6. The assay of claim 1 , wherein the polypeptide is identical to the polypeptide of SEQ ID NO:36.